Jeannerat, AnnickPeneveyre, CedricArmand, FlorenceChiappe, DiegoHamelin, RomainScaletta, CorinneHirt-Burri, NathalieRoessingh, Anthony de BuysRaffoul, WassimApplegate, Lee AnnLaurent, Alexis2021-12-182021-12-182021-12-182021-11-0110.3390/cells10112872https://infoscience.epfl.ch/handle/20.500.14299/183955WOS:000724942900001Human fetal progenitor tenocytes (hFPT) produced in defined cell bank systems have recently been characterized and qualified as potential therapeutic cell sources in tendon regenerative medicine. In view of further developing the manufacture processes of such cell-based active pharmaceutical ingredients (API), the effects of hypoxic in vitro culture expansion on key cellular characteristics or process parameters were evaluated. To this end, multiple aspects were comparatively assessed in normoxic incubation (i.e., 5% CO2 and 21% O-2, standard conditions) or in hypoxic incubation (i.e., 5% CO2 and 2% O-2, optimized conditions). Experimentally investigated parameters and endpoints included cellular proliferation, cellular morphology and size distribution, cell surface marker panels, cell susceptibility toward adipogenic and osteogenic induction, while relative protein expression levels were analyzed by quantitative mass spectrometry. The results outlined conserved critical cellular characteristics (i.e., cell surface marker panels, cellular phenotype under chemical induction) and modified key cellular parameters (i.e., cell size distribution, endpoint cell yields, matrix protein contents) potentially procuring tangible benefits for next-generation cell manufacturing workflows. Specific proteomic analyses further shed some light on the cellular effects of hypoxia, potentially orienting further hFPT processing for cell-based, cell-free API manufacture. Overall, this study indicated that hypoxic incubation impacts specific hFPT key properties while preserving critical quality attributes (i.e., as compared to normoxic incubation), enabling efficient manufacture of tenocyte-based APIs for homologous standardized transplant products.Cell Biologyactive pharmaceutical ingredientscell bankingcell manufacturehypoxiahuman progenitor tenocytesoptimizationproteomicsregenerative medicinestandardized transplantstendon affectionsmesenchymal stem-cellslow-oxygen tensionosteogenic differentiationgene-expressionproliferationcycleidentificationhif-1-alphametabolismexpansiontext::journal::journal article::research article